Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris
Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
Acne is a chronic inflammatory dermatosis of the pilosebaceous unit. Topical treatment is the
first choice in mild and moderate cases of acne, especially topical retinoids. Although
topical retinoids are very effective in the treatment of acne, local cutaneous irritation
including burning, itching, erythema, peeling or dryness, is observed in a considerable
number of patients, resulting in low patient compliance, compromising the efficacy of the
therapy.
Several approaches have been proposed to address these concerns, including the use of esters
of retinoic acid (RA) and RA precursors, such as retinol and retinaldehyde, or novel drug
delivery systems, which present the potential for controlled release, in turn reducing the
aforementioned occurrences.
Encapsulation of retinoids into vesicular carriers as liposomes and ethosomes and
nanoparticulate carriers can significantly improve their effects for the treatment of acne
compared with commercial formulations , providing better tolerability of irritating retinoid.
The aim of work is to assess the efficacy and tolerability of the topical application of
Retinyl Palmitate-loaded ethosome formulation in the treatment of acne vulgaris in comparison
to conventional formulation of classic retinoids